Roche Personalised Breast Cancer Drug Approved

As reported by the PharmaTimes, Roche’s new personalised medicine for HER2-positive metastatic breast cancer has been approved by the US Food and Drug Administration (FDA).

Roche Personalised Breast Cancer Drug Approved by FDAThe drug, called Perjeta combines Roche’s Herceptin drug along with chemotherapy. It works by targeting a different part of the HER-protein than Herceptin does. This resulted in a further reduction in growth of the HER2-positive breast cancer cells and prevents them from surviving.

Approval from the FDA came as a result of a successful Phase III study which found that patients who took a combination of Perjeta, Herceptin and docetaxel lived 6.1 months longer without their cancer getting worse.

Speaking of the FDA approval, Chief Medical Officer and Head of Global Product Development at Roche, Hall Barron, stated, “Today’s approval of Perjeta is an important advance in the treatment of HER2-positive

metastatic breast cancer.  Perjeta attacks HER2-positive tumours differently than Herceptin. Based on the way the two medicines work together, the combination plus chemotherapy can prolong the time before this aggressive cancer worsens compared to Herceptin and chemotherapy alone. We are very pleased to see our efforts in studying the science of HER2 translate into another personalized medicine.”

Search our Pharmaceutical Jobs in the UK and Europe

 

Are you looking for a job in the Pharmaceutical Industry?

Click here to search our pharmaceutical jobs online now.

Posted in: Industry News, News
CK Logo in place of featured image